Patents by Inventor Hisayoshi Ooka

Hisayoshi Ooka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-VEGF human monoclonal antibody
    Patent number: 5730977
    Abstract: The present invention provides an anti-VEGF human monoclonal antibody capable of binding to human VEGF to neutralize its activity, a cell strain producing said human monoclonal antibody, and a vascularization inhibitor containing said human monoclonal antibody. Hybridoma strains VA01 and BL2 producing the anti-VEGF human monoclonal antibody can also be provided according to the present invention by transformation with Epstein-Barr Virus (EBV) of human lymphocyte producing anti-human VEGF antibody and then fusing the transformant cells with human myeloma cells. The monoclonal antibody of the present invention can serve as a vascularization inhibitor which is useful for human because it is derived from human and capable of binding specifically to VEGF participating in vascularization, to inhibit the migration or proliferation of vascular endothelial cells.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: March 24, 1998
    Assignee: Mitsui Toatsu Chemicals, Inc.
    Inventors: Hisayoshi Ooka, Shiro Takagi, Izumi Mita, Noboru Satozawa, Ayako Watanabe, Tomoko Yokomatsu
  • Transformed cell lines producing human monoclonal antibodies specific for Pseudomonas aeruginosa serotypes
    Patent number: 5521085
    Abstract: The present invention relates to human monoclonal antibodies capable of plurally binding with O-antigens of Pseudomonas aeruginosa, relates to novel parent cell lines for producing human hybridomas derived from human immunoglobulin synthesizing cells, which cell lines themselves incapable of producing human immunoglobulin and capable of fusing with human antibody-producing cells, relates to human-human hybridomas which can secrete monoclonal antibodies capable of binding with at least one of serotypes of Pseudomonas aeruginosa, relates to pharmaceutical compositions for prophylaxis or therapy of Pseudomonas aeruginosa infectious diseases, and relates to prophylactic or therapeutic methods for Pseudomonas aeruginosa infectious diseases.
    Type: Grant
    Filed: April 1, 1993
    Date of Patent: May 28, 1996
    Assignee: Mitsui Toatsu Chemicals, Inc.
    Inventors: Tamotsu Fukuda, Yasushi Ono, Shiro Shigeta, Yasuyuki Kuriowa, Hisayoshi Ooka